Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US8342033094
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG0024L5B86
SLNO
Soleno Therapeutics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Soleno Therapeutics Inc
ISIN
US8342033094
TICKER
SLNO
MIC
XNAS
REUTERS
SLNO.OQ
BLOOMBERG
SLNO US
Sun, 12.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If y...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 11.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 11.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you pu...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If yo...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 9, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4,...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mai...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       Soleno Therapeutics
US8342033094

Did you buy SLNO common stock between March 26, 2025, and November 4, 2025?Affected Soleno Therapeutics, Inc. Investor SummaryWho: Soleno Therapeutics, Inc. (NASDAQ: SLNO)What: Securities fraud class action lawsuit filedClass Period: March 26, 2025, through November 4, 2025Deadline to Seek Lead Plaintiff Status: May 5, 2026Key Lawsuit Allegations:...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 8, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO)....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 07.04.2026       Soleno Therapeutics
US8342033094

Levi & Korsinsky, LLP alerts investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of a pending securities class action. Class Period: March 26, 2025 through November 4, 2025. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.A class action has been filed in the U.S. Dist...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 7, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 7, 2026) - Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.Should You Join The Soleno Clas...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encourage...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If yo...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Soleno Therapeutics
US8342033094

MILWAUKEE, April 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Soleno (NASDAQ: SLNO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Neurocrine. Click here to learn h...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Soleno Therapeutics
US8342033094

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Soleno Therapeutics, Inc. (NASDAQ: SLNO) to Neurocrine Biosciences for $53.00 per share in cash.Halper Sadeh encourages Soleno shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 06.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inc...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 05.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If yo...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       Soleno Therapeutics
US8342033094

NEW ORLEANS, April 3, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 5, 2026 to file lead plaintiff applications in a securities class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO), if they purchased or otherwise acquired the Compa...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 3, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Soleno Therapeutics
US8342033094

BENSALEM, Pa., April 3, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SOLENO THERAPEUTICS, INC. (SL...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Soleno Therapeutics
US8342033094

Did you buy SLNO common stock between March 26, 2025, and November 4, 2025?Affected Soleno Therapeutics, Inc. Investor SummaryWho: Soleno Therapeutics, Inc. (NASDAQ: SLNO)What: Securities fraud class action lawsuit filedClass Period: March 26, 2025, through November 4, 2025Deadline to Seek Lead Plaintiff Status: May 5, 2026Key Lawsuit Allegations:...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If yo...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mai...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - April 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Sole...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, April 1, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) have opportunity to lead the securities fraud class action lawsuit....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Soleno Therapeutics
US8342033094

SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Soleno Therapeutics
US8342033094

Alert: Claims Focus on Alleged Misrepresentations About Clinical Trial Integrity and Drug SafetyNEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities of a pending securities class action....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Soleno Therapeutics
US8342033094

NEW YORK, March 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates in...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 31, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the common stock of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inc...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Soleno Therapeutics
US8342033094

NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encourag...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If y...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Soleno Therapeutics
US8342033094

SLNO Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO, March 30, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If y...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 29.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If y...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.03.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.03.2026       Soleno Therapeutics
US8342033094

NEW YORK and NEW ORLEANS, March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO) of a class action securities lawsuit.   CLASS DEFINITION: The...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If y...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Soleno Therapeutics
US8342033094

SLNO Investors with Losses Encouraged to Contact the FirmSAN FRANCISCO, March 26, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Soleno Therapeutics
US8342033094

NEW YORK, March 26, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates in...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Soleno Therapeutics
US8342033094

Did you buy SLNO common stock between March 26, 2025, and November 4, 2025?Affected Soleno Therapeutics, Inc. Investor SummaryWho: Soleno Therapeutics, Inc. (NASDAQ: SLNO)What: Securities fraud class action lawsuit filedClass Period: March 26, 2025, through November 4, 2025Deadline to Seek Lead Plaintiff Status: May 5, 2026Key Lawsuit Allegations:...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink